{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:57:43Z","timestamp":1785549463376,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.08.001","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"303-313","source":"Crossref","is-referenced-by-count":25,"title":["Treatment strategies for CML"],"prefix":"10.1016","volume":"22","author":[{"given":"John M.","family":"Goldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.08.001_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2141.2000.02137.x","article-title":"The story of chronic myeloid leukaemia","volume":"110","author":"Geary","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2009.08.001_bib2","first-page":"201","article-title":"Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy","author":"Medical Research Council's Working Party for Therapeutic Trials in Leukaemia","year":"1968","journal-title":"Br Med J"},{"key":"10.1016\/j.beha.2009.08.001_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of Ph1 positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2009.08.001_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia","author":"Goldman","year":"1982","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.beha.2009.08.001_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukaemia","author":"Speck","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.08.001_bib6","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198604243141701","article-title":"Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia","volume":"314","author":"Talpaz","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.08.001_bib7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","author":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J. Med"},{"key":"10.1016\/j.beha.2009.08.001_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.08.001_bib9","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alfa: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.08.001_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low- dose Ara-C for newly diagnosed chronic phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.08.001_bib12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of imatinib therapy for chronic-phase chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.08.001_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"213","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.08.001_bib15","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia in chronic phase: incidence of sustained responses in an intention to treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.08.001_bib16","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High dose imatinib mesylate therapy in newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V112.11.447.447","article-title":"Imatinib (IM) pharmacokinetics (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS])","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2009.08.001_bib19","first-page":"980","article-title":"The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations","volume":"87","author":"Marin","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.08.001_bib20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.08.001_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.08.001_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.187.187","article-title":"Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from the French pilot study and first results of the multicentre \u2018Stop Imatinib (STIM) study","volume":"112","author":"Mahon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib24","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. recommendations from an expert panel on behalf of the European leukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib25","doi-asserted-by":"crossref","unstructured":"Baccarani M, Cortes J, Pane F, et\u00a0al. Chronic myeloid leukemia: an update of concepts and management recommendations of the European LeukemiaNet. J Clin Ocol, in press, doi:10.1200\/JCO.2009.25.0779.","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"10.1016\/j.beha.2009.08.001_bib26","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib27","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib29","unstructured":"Milojkovic D, Nicholson M, Apperley JF, et\u00a0al. Early prediction of success or failure using second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Haematologica, in press."},{"key":"10.1016\/j.beha.2009.08.001_bib30","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.V98.7.2039","article-title":"Chronic myeloid leukemia: current treatment options","volume":"98","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib31","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. Chronic leukemia working party of the European Group for Blood and Marrow Transplantation","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2009.08.001_bib32","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1038\/bmt.2008.282","article-title":"Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT","volume":"42","author":"Suttorp","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2009.08.001_bib33","doi-asserted-by":"crossref","unstructured":"Garg RJ, Kantarjian HM, O'Brien S, et\u00a0al. The use of nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors (TKI): long-term follow-up. Blood, in press, doi:10.1182\/blood-2009-05-221531.","DOI":"10.1182\/blood-2009-05-221531"},{"key":"10.1016\/j.beha.2009.08.001_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V112.11.183.183","article-title":"Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (CP): first results of the Phase III (SPIRIT) trial from the French CML Group (FI LMC)","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib35","article-title":"Efficacy of nilotinib (formerly AMN107) in patients with newly diagnosed previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2009.08.001_bib36","article-title":"Dasatinib (SPRYCEL) in patients with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)","volume":"112","author":"Cortes","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2009.08.001_bib37","unstructured":"Goldman JM, Majhail NS, Klein J, et\u00a0al. Myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase: incidence of relapse and late mortality in 5-year survivors, submitted for publication."},{"key":"10.1016\/j.beha.2009.08.001_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib39","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.08.001_bib41","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.08.001_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/asheducation-2005.1.118","article-title":"Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia","author":"Ottmann","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2009.08.001_bib43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/asheducation-2007.1.435","article-title":"Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges","author":"Thomas","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:59:13Z","timestamp":1590281953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000565"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.08.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}